Relationships among neurocognition, symptoms and functioning in patients with schizophrenia: A path-analytic approach for associations at baseline and following 24 weeks of antipsychotic drug therapy

BMC Psychiatry

Volumn 9, Issue , 2009, Pages

  Lipkovich, Ilya A ^a   Deberdt, Walter ^b   Csernansky, John G ^c   Sabbe, Bernard ^d   Keefe, Richard S E ^e   Kollack Walker, Sara ^a  

^a ELI LILLY AND COMPANY   (United States)

^b Eli Lilly Benelux   (Belgium)

^c NORTHWESTERN UNIVERSITY   (United States)

^d UNIVERSITY OF ANTWERP   (Belgium)

^e DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE; BENZODIAZEPINE DERIVATIVE;

ADULT; ARTICLE; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HEINRICHS CARPENTER QUALITY OF LIFE SCALE; HUMAN; MALE; MENTAL FUNCTION; NEGATIVE SYNDROME; POSITIVE AND NEGATIVE SYNDROME SCALE; POSITIVE SYNDROME; PSYCHOLOGICAL RATING SCALE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SOCIAL PSYCHOLOGY; TREATMENT DURATION; VERBAL MEMORY; WORKING MEMORY; COGNITIVE DEFECT; COMPARATIVE STUDY; FOLLOW UP; NEUROPSYCHOLOGICAL TEST; PSYCHOLOGY; PSYCHOMETRY; STATISTICS; TREATMENT OUTCOME;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; COGNITION DISORDERS; FEMALE; FOLLOW-UP STUDIES; HALOPERIDOL; HUMANS; MALE; NEUROPSYCHOLOGICAL TESTS; PSYCHIATRIC STATUS RATING SCALES; PSYCHOMETRICS; QUALITY OF LIFE; RISPERIDONE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME;

EID: 68449086874     PISSN: None     EISSN: 1471244X     Source Type: Journal    
DOI: 10.1186/1471-244X-9-44     Document Type: Article

References (31)

1. Green MF What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 1996, 153:321-330 8610818
2. Green MF Kern RS Braff DL Mintz J Neurocognitive deficits and functional outcome in schizophrenia: Are we measuring the "right stuff"? Schizophr Bull 2000, 26:119-136 10755673
3. Breier A Schreiber JL Dyer J Pickar D National Institute of Mental Health longitudinal study of chronic schizophrenia. Prognosis and predictors of outcome Arch Gen Psychiatry 1991, 48:239-246 1671741
4. Ho BC Nopoulos P Flaum M Arndt S Andreasen NC Two-year outcome in first-episode schizophrenia: Predictive value of symptoms for quality of life Am J Psychiatry 1998, 155:1196-1201 9734542
5. Wieselgren IM Lindstrom E Lindstrom LH Symptoms at index admission as predictor for 1-5 year outcome in schizophrenia Acta Psychiatr Scand 1996, 94:311-319 10.1111/j.1600-0447.1996.tb09866.x 9124077
6. Heslegrave RJ Awad AG Voruganti LN The influence of neurocognitive deficits and symptoms on quality of life in schizophrenia J Psychiatry Neurosci 1997, 22:235-243 1188864 9262045
7. Norman RM Malla AK Cortese L Cheng S Diaz K McIntosh E McLean TS Rickwood A Voruganti LP Symptoms and cognition as predictors of community functioning: A prospective analysis Am J Psychiatry 1999, 156:400-405 10080555
8. Velligan DI Mahurin RK Diamond PL Hazleton BC Eckert SL Miller AL The functional significance of symptomatology and cognitive function in schizophrenia Schizophr Res 1997, 25:21-31 10.1016/S0920-9964(97)00010-8 9176924
9. Dickerson F Boronow JJ Ringel N Parente F Social functioning and neurocognitive deficits in outpatients with schizophrenia: A 1-year follow-up Schizophr Res 1999, 37:13-20 10.1016/S0920-9964(98)00134-0 10227104
10. Kurtz MM Moberg PJ Ragland JD Gur RC Gur RE Symptoms versus neurocognitive test performance as predictors of psychosocial status in schizophrenia: A 1- and 4-year prospective study Schizophr Bull 2005, 31:167-174 10.1093/schbul/sbi004 15888434
11. Mohamed S Rosenheck R Swartz M Stroup S Lieberman JA Keefe RSE Relationship of cognition and psychopathology to functional impairment in schizophrenia Am J Psychiatry 2008, 165:978-987 10.1176/ appi.ajp.2008.07111713 18450928
12. Perlick DA Rosenheck RA Kaczynski R Bingham S Collins J Association of symptomatology and cognitive deficits to functional capacity in schizophrenia Schizophr Res 2008, 99:192-199 10.1016/ j.schres.2007.08.009 17851042
13. Harvey PD Ziprasidone and cognition: The evolving story J Clin Psychiatry 2003, 64(Suppl 19):33-39 14728088
14. Bowie CR Reichenberg A Patterson TL Heaton RK Harvey PD Determinants of real-world functional performance in schizophrenia subjects: correlations with cognition, functional capacity, and symptoms Am J Psychiatry 2006, 163:418-425 10.1176/appi.ajp.163.3.418 16513862
15. Bowie CR Leung WW Reichenberg A McClure MM Patterson TL Heaton RK Harvey PD Predicting schizophrenia patients' real-world behavior with specific neuropsychological and functional capacity measures Biol Psychiatry 2008, 63:505-511 2335305 17662256 10.1016/j.biopsych.2007.05.022
16. Keefe RS Young CA Rock SL Purdon SE Gold JM Breier A HGGN Study Group One-year double-blind study of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in schizophrenia Schizophr Res 2006, 81:1-15 10.1016/j.schres.2005.07.038 16202565
17. Heinrichs DW Hanlon TE Carpenter WT Jr The Quality of Life Scale: An instrument for rating the schizophrenic deficit syndrome Schizophr Bull 1984, 10:388-398 6474101
18. Kay SR Fiszbein A Opler LA The positive and negative syndrome scale (PANSS) for schizophrenia Schizophr Bull 1987, 13:261-276 3616518
19. Nuechterlein KH Barch DM Gold JM Goldberg TE Green MF Heaton RK Identification of separable cognitive factors in schizophrenia Schizophr Res 2004, 72:29-39 10.1016/j.schres.2004.09.007 15531405
20. Dickinson D Ragland JD Calkins ME Gold JM Gur RC A comparison of cognitive structure in schizophrenia patients and healthy controls using confirmatory factor analysis Schizophr Res 2006, 85:20-29 10.1016/ j.schres.2006.03.003 16616831
21. The Psychological Corporation WAIS-III and WMS-III Technical Manual San Antonio: The Psychological Corporation 1998
22. Keefe RS Bilder RM Harvey PD Davis SM Palmer BW Gold JM Meltzer HY Green MF Miller del D Canive JM Adler LW Manschreck TC Swartz M Rosenheck R Perkins DO Walker TM Stroup TS McEvoy JP Lieberman JA Baseline neurocognitive deficits in the CATIE schizophrenia trial Neuropychopharmacology 2006, 31:2033-2046 10.1038/sj.npp.1301072
23. Brebion G Gorman JM Malaspina D Sharif Z Amador Z Clinical and cognitive factors associated with verbal memory task performance in patients with schizophrenia Am J Psychiatry 2001, 158:758-764 10.1176/ appi.ajp.158.5.758 11329399
24. Hartman M Steketee MC Silva S Lanning K McCann H Working memory and schizophrenia: Evidence for slowed encoding Schizophr Res 2002, 59:99-113 10.1016/S0920-9964(01)00366-8
25. Morrens M Hulstijn W Sabbe B Psychomotor slowing in schizophrenia Schizophr Bull 2007, 33:1038-1053 2632327 17093141 10.1093/schbul/sbl051
26. Green MF Nuechterlein KH Should schizophrenia be treated as a neurocognitive disorder? Schizophr Bull 1999, 25:309-318 10416733
27. Hughes C Kumari V Soni W Das M Binneman B Drozd S O'Neil S Mathew V Sharma T Longitudinal study of symptoms and cognitive function in chronic schizophrenia Schizophr Res 2002, 59:137-146 10.1016/ S0920-9964(01)00393-0
28. Rodriguez-Sanchez JM Crespo-Facorro B Gonzalez-Blanch C Perez-Iglesias R Vazques-Barquero JL PAFIP Group Study Cognitive dysfunction in first-episode psychosis: The processing speed hypothesis Br J Psychiatry Suppl 2007, 51:s107-110 10.1192/bjp.191.51.s107 18055925
29. Kaiser W Cognitive effects of antipsychotics in schizophrenia and relationship to quality of life Br J Psychiatry 2000, 176:92-93 10.1192/ bjp.176.1.92-a 10789338
30. Sharma T Cognitive effects of antipsychotics in schizophrenia and relationship to quality of life Br J Psychiatry 2000, 176:92-93 10.1192/ bjp.176.1.92
31. Brekke J Kay DD Lee KS Green MF Biosocial pathways to functional outcome in schizophrenia Schizophr Res 2005, 80:213-225 10.1016/ j.schres.2005.07.008 16137859